RecruitingNot ApplicableNCT07361263

Plasma Oxytocin Response to Oral Estrogens in Healthy Controls and AVP-Deficiency

Plasma Oxytocin in Response to Oral Estradiol Valerate and Ethinylestradiol in Healthy Controls and Patients With AVP-Deficiency

Sponsor

University Hospital, Basel, Switzerland

Enrollment

28 participants

Start Date

Jan 9, 2026

Study Type

INTERVENTIONAL

Conditions

Diabetes Insipidus AVP Deficiency

Summary

The PHOENIX study aims to investigate whether oral estradiol valerate (EV) and ethinylestradiol (EE) can stimulate oxytocin (OXT) and neurophysin-1 (NP-1) release in humans. The goal is to assess their potential as a safe diagnostic stimulation test for oxytocin deficiency, particularly in patients with arginine vasopressin (AVP) deficiency.

Eligibility

Min Age: 18 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called esthinylestradiol and a drug called estradiol valerate for people with avp deficiency and diabetes insipidus. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 50 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.